Head-To-Head Survey: Precigen (PGEN) and Its Competitors

Precigen (NASDAQ: PGEN) is one of 35 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Precigen to related companies based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, risk, dividends and valuation.

Earnings and Valuation

This table compares Precigen and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Precigen $90.72 million -$322.32 million -3.90
Precigen Competitors $1.24 billion $44.58 million 10.18

Precigen’s rivals have higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

74.1% of Precigen shares are held by institutional investors. Comparatively, 51.1% of shares of all “Commercial physical research” companies are held by institutional investors. 44.0% of Precigen shares are held by insiders. Comparatively, 17.9% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares Precigen and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Precigen -324.38% -65.28% -24.60%
Precigen Competitors -123.36% -4.32% -3.12%

Analyst Recommendations

This is a summary of current ratings and target prices for Precigen and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precigen 0 0 0 0 N/A
Precigen Competitors 193 873 1653 80 2.58

As a group, “Commercial physical research” companies have a potential upside of 42.73%. Given Precigen’s rivals higher probable upside, analysts clearly believe Precigen has less favorable growth aspects than its rivals.

Risk and Volatility

Precigen has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Precigen’s rivals have a beta of 10.27, suggesting that their average stock price is 927% more volatile than the S&P 500.


Precigen rivals beat Precigen on 8 of the 10 factors compared.

About Precigen

Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.